These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12359445)

  • 1. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.
    Liu W; Gao F; Zhao KN; Zhao W; Fernando GJ; Thomas R; Frazer IH
    Virology; 2002 Sep; 301(1):43-52. PubMed ID: 12359445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity.
    Shi W; Bu P; Liu J; Polack A; Fisher S; Qiao L
    J Virol; 1999 Sep; 73(9):7877-81. PubMed ID: 10438884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
    Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
    J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
    Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
    J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK; Cheng SC; Sin FW; Xie Y
    Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.
    Kim MS; Sin JI
    Immunology; 2005 Oct; 116(2):255-66. PubMed ID: 16162274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.
    Tindle RW; Croft S; Herd K; Malcolm K; Geczy AF; Stewart T; Fernando GJ
    Clin Exp Immunol; 1995 Aug; 101(2):265-71. PubMed ID: 7544248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity.
    Osen W; Peiler T; Ohlschläger P; Caldeira S; Faath S; Michel N; Müller M; Tommasino M; Jochmus I; Gissmann L
    Vaccine; 2001 Jul; 19(30):4276-86. PubMed ID: 11457555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies.
    Cid-Arregui A; Juárez V; zur Hausen H
    J Virol; 2003 Apr; 77(8):4928-37. PubMed ID: 12663798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes.
    Doan T; Chambers M; Street M; Fernando GJ; Herd K; Lambert P; Tindle R
    Virology; 1998 May; 244(2):352-64. PubMed ID: 9601506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation.
    Kotecha MT; Afghan RK; Vasilikopoulou E; Wilson E; Marsh P; Kast WM; Davies DH; Caparros-Wanderley W
    Vaccine; 2003 Jun; 21(19-20):2506-15. PubMed ID: 12744885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
    J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
    Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
    Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.
    Smahel M; Síma P; Ludvíková V; Marinov I; Pokorná D; Vonka V
    Vaccine; 2003 Mar; 21(11-12):1125-36. PubMed ID: 12559790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R; Gissmann L; Osen W
    Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccines against HPV-16 E7-expressing tumour cells.
    De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A
    Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Transformation activity and antigenicity of the human papillomavirus type 58 E6E7 fusion gene mutant].
    Wang H; Yu JY; Li L
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):491-6. PubMed ID: 24257298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
    Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
    Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.